R Squared’s Akero Therapeutics AKRO Stock Holding History

R Squared’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-390	Closed	-$10.8K	–	325
2024 Q4	$10.8K	Buy	+390	New	+$11.8K	0.01%	1124

Other funds holding AKRO

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

R Squared's AKRO Position: Q1 2025 in Review

R Squared sold out of Akero Therapeutics (AKRO) in Q1 2025, closing a stake of 390 shares — an estimated $10.8K sold.

R Squared first reported a position in AKRO in Q4 2024 and held it in 1 quarter. The position peaked at $10.8K in Q4 2024. 240 funds tracked by Wall St. Rank hold AKRO as of Q1 2025.

R Squared reported no remaining Akero Therapeutics position as of Q1 2025 after selling out during the quarter.
R Squared sold 390 Akero Therapeutics shares in Q1 2025, an estimated $10.8K.
R Squared first reported a position in Akero Therapeutics in Q4 2024 and held it in 1 quarter.
R Squared's Akero Therapeutics position peaked at $10.8K in Q4 2024.
240 funds tracked by Wall St. Rank held Akero Therapeutics as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.